FDA Investigator Tammy L Chavis

Tammy L Chavis has conducted inspections on 103 sites in 1 countries as of 09 Sep 2005. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
103
Last Inspection Date:
09 Sep 2005
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Tammy L Chavis:
Alicia M Mozzachio, Alla Kachko, PhD, Althea A Williams, Amy N Chen, Anastasia I Offordile, Anastasia M Shields, Anissa M Cheung, Anita R Michael, Ann L Demarco, Ann Marie Montemurro, Ann Marie Schofield, Anthony A Charity, Audrey Thereset Uy, Brandi L Garbutt, Brandy N Lepage, Brentley S Collins, Brian S Keefer, Burnell M Henry, Carol A Robles, CDR Jeremy L Wally, PhD, Chao Ming Tsai, Christian D Lynch (CDL), Christina J Sauder, PhD, Christina K Theodorou, Christopher J Adams, Craig D Zagata, Cynthia Jim, CSO, Cynthia White, Daniel J Min, Daniel T Lee, Darlene C Plank Turlington, Dauksism, Dave Hafner, David A Oluwo, David J Hafner, Dawn D Aiello, Deborah J Parris, Debra J Bennett, Debra L Pagano, Denise M Digiulio, Derek S Dealy, Djamila Harouaka, Donald L Lech, Donald W Myrick, Dr. Guang Gao, PhD, Dr. Mark J Seaton, PhD, Edward D Mcdonald, Eileen A Liu, Ellen Huang, Erika M Wilkerson, Erika V Butler, Erin L Mcfiren, Gayle S Lawson, Gene D Arcy, George Pyramides, Gerald W Kopp, Hala L Selby, Hala Lj Whetstone, Haruhiko Murata, Helen B Ricalde, J David Doleski, Jacob M Dyer, Jacqueline Mdiaz Albertini, James M Mason, James P Mcevoy, James R Birkenstamm, Jason M Sluzynski, Javier E Santos, Jean Blackston Hill, Jeannie R Mayberry, Joan A Loreng, Joan Adamo, Joanne Hajoway, Joanne Heim, Joanne M Hajoway, Joseph George, Joseph L Despins, PhD, Joseph T Dougherty, Juanita P Versace, Jude C Dikes, Judith A Paterson, Julianne C Mccullough, Junho Pak, Karyn M Campbell, Kathleen B Mihalik, Kathryn Carbone, MD, Kelly N Kerr, Kendra L Brooks, Kenneth M Gordon, Kimberly A Dux, Ko U Min, Kristen D Evans, Kristina J Donohue, Kristina L Conroy, Kyle S Hobson, Lauren N Barber, Lawrence Harmon, Jr, LCDR Margaret Edi Gennaro, Linda M Ross, Linda Thai, Lisa B Orr, Lisa M Bellows, Lisa M Feola, Lori Peters, Lori S Lawless, LT John M Mastalski, LTJG Bradley E Benasutti, LTJG Lauren N Shade, Luella J Rossi, Luis A Dasta, Magdi Ali, Marc A Jackson, Jr, Marcelo O Mangalindan, Jr, Marea K Harmon, Margaret M Sands, Maria A Reed, Marian E Major, PhD, Martha Sullivan Myrick, Matthew R Noonan, Maureen A Wentzel, Meredith L Sheridan, Michael A Taylor, Michael Curbarg, Michael D Omeara, Michael Gurbarg, Michael J Nerz, Michael L Casner, Michele M Falchek, Mihaly S Ligmond, Mike M Rashti, Nicole K Trudel, Norman K Starks, Omotunde O Osunsanmi, Patricia D Gardner, Paula A Trost, Prabhu P Raju, Qiao Y Bobo, Rabin N Ghoshal, Rachael O Oyewole, Rahi D Patel, Ralph A Erickson, Ramon E Martinez, Rebecca K Olin, Richard E Needham, Rita F Larocca Mahoney, Robert B Shibuya, MD, Robert D Tollefsen, Robert J Maffei, Robert Jennings, Rochelle L Massey, Ronald A Stokes, Ronald T Nowalk, Rose Ashley, Ruben C Quintana, Rw Mccullough, Sam Pepe, Scott E Norris, Sean D Duke, Seng Ching Hwang, Sheila Dreher Lesnick, Shelley L Waring, Shuang Tang, Simone E Pitts, Stephanie Mangigian, MS/OSH, RN, Stephen D Brown, Stephen J Koniers, Steven A Rubin, Susan F Laska, MS, Susan M Jackson, Tekalign Wondimu, Temar Q Williams, Thomas E Friel, Tiffani D Wilson, Tina S Roecklein, Todd J Maushart, Tonya O Corbin, Vlada Matusovsky, Wei Wang, PhD, Whitney S Reynolds, Xiao Wang, Yvette I Henry, Yvette I Johnson, Yvonne C Mcknight

Tammy L Chavis's Documents

Publish Date Document Type Title
January, 2002 EIR AstraZeneca Pharmaceuticals LP - EIR, 2002-01-14
September, 2000 FDA 483 Wyeth-Ayerst Pharmaceuticals, Inc - Form 483, 2000-09-22
June, 2001 EIR Charles River Laboratories, Inc. - EIR, 2001-06-14
May, 2003 EIR Merck Sharp & Dohme LLC - EIR, 2003-05-14
June, 2005 EIR SPI Pharma Inc - EIR, 2005-06-20
April, 2002 FDA 483 AIRGAS USA, LLC - Form 483, 2002-04-10
January, 2003 FDA 483 SPI Pharma Inc - Form 483, 2003-01-27
September, 2000 EIR Wyeth Division of Wyeth Pharmaceuticals, Inc. - EIR, 2000-09-21
April, 2002 EIR AIRGAS USA, LLC - EIR, 2002-04-10
September, 2000 EIR Wyeth-Ayerst Pharmaceuticals, Inc - EIR, 2000-09-22
June, 2005 FDA 483 SPI Pharma Inc - Form 483, 2005-06-20
June, 2004 FDA 483 AstraZeneca Pharmaceuticals LP - Form 483, 2004-06-24
February, 2003 FDA 483 Snow Pharmaceuticals, LLC - Form 483, 2003-02-06
May, 2001 EIR Noramco, LLC - EIR, 2001-05-08
January, 2004 FDA 483 PEL HEALTHCARE LLC - Form 483, 2004-01-09
April, 2003 EIR Pharmalog Inc. Pharmaceutical Services - EIR, 2003-04-01
January, 2004 FDA 483 Response PEL HEALTHCARE LLC - Form 483R, 2004-01-22
May, 2005 EIR Eurofins Lancaster Laboratories, Inc - EIR, 2005-05-12
May, 2001 FDA 483 Noramco, LLC - Form 483, 2001-05-08
June, 2005 FDA 483 Response SPI Pharma Inc - Form 483R, 2005-07-14
February, 2004 EIR Eurofins Lancaster Laboratories, Inc - EIR, 2004-02-26
June, 2001 FDA 483 Charles River Laboratories, Inc. - Form 483, 2001-06-14
July, 2000 FDA 483 IGI, Inc. - Form 483, 2000-07-05
January, 2004 EIR PEL HEALTHCARE LLC - EIR, 2004-01-09
August, 2002 EIR AIRGAS USA, LLC - EIR, 2002-08-23
February, 2003 EIR Procter and Gamble Dover Wipes Company - EIR, 2003-02-12
June, 2001 FDA 483 Response Charles River Laboratories, Inc. - Form 483R, 2001-07-10
October, 2003 EIR SPI Pharma, Inc. - EIR, 2003-10-23

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more